VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - March 16, 2005) - WEX
Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) is pleased to
announce that it has mutually decided with its European partner,
Laboratorios del Dr. Esteve S.A. ("ESTEVE") to make certain amendments
to the previously executed License and Collaboration Agreement relating
to the Company's products Tectin(TM), Tetrodin(TM) and Tocudin(TM). The
amendments expand the existing collaboration to include additional
co-development work. Both parties agree that to achieve
commercialization of Tectin(TM) in the most expeditious manner it is
necessary to effectively utilize their combined resources. ESTEVE will
pursue development in Europe and is planning to commence a double blind
placebo controlled study in Europe later this year.
